AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.

Exclusion Criteria

• •Any significant laboratory finding or any severe and uncontrolled medical condition.
• •Active CNS involvement by lymphoma, leptomeningeal disease, or spinal cord compression.
• •Serologic active HBV or HCV infection.
• •Known to have tested positive for HIV.
• •Active gastrointestinal disease or other condition that will interfere with oral therapy.
• •Any of the following cardiac criteria:
• •* Mean resting QTcF \> 470 msec or clinically important abnormalities in rhythm (ventricular arrhythmias and uncontrolled atrial fibrillation)
• •* Factors that increase the risk of QTc prolongation or risk of arrhythmic events
• •* Cardiac procedures or conditions within the last 6 months: Coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI) or heart valve intervention vascular stent implantation, acute coronary syndrome / myocardial infarction, uncontrolled angina pectoris, use of therapeutic anti-coagulation for treatment of active thromboembolic events.
• •* Severe valvular heart disease
• •* Congestive heart failure Grade II to Grade IV
• •* Prior or current cardiomyopathy
• •* Uncontrolled hypertension
• •* Brain perfusion problems such as haemorrhagic or thrombotic stroke (including transient ischemic attacks)
• •Unresolved non-haematological toxicities of Grade \> 1 from prior anticancer therapy (excluding peripheral neuropathy, vitiligo, alopecia, and endocrine disorders that are controlled with replacement hormone therapy, and asymptomatic laboratory abnormalities), unless immune-mediated.
• •History of another primary malignancy.
• •History of significant haemoptysis or haemorrhage within 4 weeks of the first dose of study treatment.
• •Requires ongoing immunosuppressive therapy, including systemic corticosteroids.
• •Prior treatment with a MAT2A inhibitor or a PRMT5 inhibitor.